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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
nicotine replacement therapy reduces the withdrawal symptom of craving, or urge to
smoke, in dependent adult smokers during smoking cessation.
STUDY DESIGN: Systematic review of three English language and peer-reviewed
randomized-controlled trials published in 2009, 2010, and 2011.
DATA SOURCES: One single-blinded randomized-controlled crossover trial, one
double-blinded, placebo controlled, randomized-controlled crossover trial, and one
single-blinded, placebo controlled, randomized-controlled crossover trial
OUTCOMES MEASURED: Withdrawal symptoms of craving, irritability, difficulty
concentrating, and restlessness were measured on a 100mm visual analog scale (VAS).
Adverse effects (AEs) of mouth and throat irritation, aching jaw, feeling sick, vomiting,
flatulence/belching, stomachache, heartburn, diarrhea, hiccups, feeling high, feeling
dizzy, headache, palpitations, sweatiness, and cold hands/feet were measured based upon
their frequency and strength. One study measured slightly different withdrawal symptoms
(depressed mood, irritability, restlessness, hunger, and poor concentration) on a Moods
and Physical Symptoms Scale (MPSS) and time spent with urges and strength of urges on
a six-point Likert Scale. This study also measured the adverse effects of feeling unwell,
nausea, throat irritation, and dizziness on a 10-point scale. Temporary smoking cessation
was measured in all three studies.
RESULTS: Thornley et al found that the active pouch significantly decreased craving in
comparison to placebo. The gum decreased craving; however, the findings were not
considered to be statistically significant. In McRobbie et al, all three types of NRT
proved to significantly decrease craving in comparison to placebo. Similarly, Shahab et
al found that both innovative and older types of NRT decreased craving. The Nicotine
Cannon was more tolerable than older types of NRT. Overall, the NRT products caused
more adverse reactions than placebo, but also led to more cases of temporary smoking
cessation.
CONCLUSION: The results of all three studies show that nicotine replacement therapy
decreases the withdrawal symptom of craving, allowing smokers to be more successful in
their attempts to quit in the short term. No one NRT product is significantly better than
another in decreasing craving.
KEY WORDS: nicotine replacement therapy, withdrawal, smoking cessation, craving

INTRODUCTION
Nicotine dependence is due to alkaloid nicotine, which is a chemical in cigarettes
that alters the dopaminergic pathway in the midbrain and trains the brain to require
nicotine to feel pleasure. Alkaloid nicotine binds to the naturally occurring nicotinic
receptors in the human brain and spinal cord, sending a message of reward, or pleasure,
throughout the body.1 With repeated stimulation of these receptors, a person builds
tolerance and requires higher levels of nicotine to feel the same positive effects. This
unending cycle ultimately leads to the body’s dependence on and addiction to nicotine.
This paper evaluates three randomized-controlled trials that compare the efficacy of
various types of nicotine replacement therapy (NRT) with placebo in preventing the
withdrawal symptom of craving in adult smokers during smoking cessation.
Although the alkaloid nicotine is responsible for the addiction to cigarettes, it is
actually the other toxins (benzene, carbon monoxide, acetic acid, formaldehyde, and
heavy metals) that are responsible for the negative health effects of smoking. Cigarette
smoking directly contributes to patients’ health and frequently complicates chronic
medical conditions and their treatments. Individuals who smoke are more likely to suffer
from chronic pulmonary and cardiovascular diseases and various carcinomas, particularly
of the lung, kidney, bladder, and cervix.2 Women who smoke during pregnancy have a
higher rate of spontaneous abortion and are at risk of giving birth to babies who are small
for gestational age.3 Currently, the prevalence of cigarette smoking in the United States is
19.3%, with people between the ages of 18 and 64 being more likely to smoke than those
over age 65.4 Because cigarette smoking is directly responsible for so many health
problems, it is important for physician assistants to be knowledgeable of both the health
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consequences of smoking and the smoking cessation options that are available for their
patients.
Although the cost per day varies depending on personal habit, the average cost of
a pack of cigarettes in the US is $5.51.5 It is important to realize, however, that some
smokers may have a multi-pack per day habit and could potentially be spending well over
$10 a day on a product that is only harming them. In fact, cigarette smoking leads to over
$100 billion in health care expenses, $67 billion in productivity losses at work, and over
$100 billion in premature deaths annually.5 Whereas a tobacco addiction can be lifelong,
treatment with NRT is only a temporary expense that will result in better health outcomes
in the future. The average daily cost of NRT varies depending on the type of product one
uses: nasal spray $3.41, patches $3.91, lozenges $4.98, gum $5.81, and inhaler $6.07.6
Approximately 70% of current smokers in the US are interested in smoking
cessation; however, they lack the knowledge of where to look for help and the emotional
support that proves to be crucial in the process of smoking cessation.1 Various methods
of smoking cessation exist, such as behavioral modification, group counseling,
Bupropion, Chantix, and NRT. Smoking cessation is an individualized process and may
require more than one attempt before finding the appropriate method that leads to a
successful outcome.
The withdrawal symptom of craving directly affects a smoker’s ability to quit
smoking by making it more difficult to resist cigarettes for long periods of time. By
using NRT, smokers are able to deliver limited amounts of nicotine to their brains in
order to decrease their craving and retrain their bodies to function without requiring
nicotine.
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OBJECTIVE
The objective of this selective EBM review is to determine whether or not
nicotine replacement therapy reduces the withdrawal symptom of craving, or urge to
smoke, in dependent adult smokers during smoking cessation.
METHODS
Criteria used for the selection of the research articles for this review was based on
population age (≥ 18 years old) and dependency on cigarette smoking. It was important
for studies to include comparisons of various nicotine replacement products (4mg
Zonnic® oral nicotine pouch, 4mg Nicorette® chewing gum, Zonnic® 1mg/spray mouth
spray, Zonnic® 2.5mg nicotine lozenge) to the usage of placebo.7,8 One of the articles
compared an innovative nicotine replacement therapy (the Nicotine Cannon) to older
NRT products (nicotine inhaler, 4mg nicotine lozenge, and 4mg nicotine mini-lozenge).9
All articles assessed patient-oriented evidence that matters (POEMs), which included
withdrawal symptoms, adverse effects of NRT usage, and temporary smoking cessation.
The author used the PubMed and Medline databases to search for peer-reviewed
randomized-controlled trials that were published in the English language within the last
five years. Important key words that were used included “nicotine replacement therapy,”
“withdrawal,” “smoking cessation,” and “craving”. The articles were selected based
upon their evaluation of POEMs and a participant pool of people ≥18 years old.
Exclusion criteria comprised of patients less than 18 years of age, those not dependent on
cigarette smoking, and articles that addressed disease-oriented evidence (DOE). The
statistics reported in the studies included 95% confidence intervals (CI), p-values, change
in mean from the baseline, independent t test, and χ2. The author calculated the numbers
needed to treat (NNT) and numbers needed to harm (NNH) using the dichotomous data
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on adverse effects and temporary smoking cessation in order to support the efficacy of
NRT use in comparison to placebo in preventing the withdrawal symptom of craving.
Table 1. Demographics & Characteristics of Included Studies
Study
Type
#
Mean Inclusion
Exclusion Criteria
people Age
Criteria
(yrs)
9
Shahab
RCT –
48
31
Over 18,
N/A
(2011)
singleregular smokers
blind,
x at least a year,
crossover
≥5 cigarettes/d,
in good health;
not pregnant;
not current
users of NRT
products
18 to 70 years
Recent (previous 6 mo)
McRobbie RCT 47
49
7
old,
smoked
15+
MI, angina, DM, other
doublecigarettes/d for at serious medical condition,
(2010)
blind,
least the last year, previous severe allergic
crossover
smoked ﬁrst
reaction, current chemical
, placebo
cigarette within
dependence other than
controlle
30 minutes of
nicotine, current
d
waking, in good
psychiatric d/o or current

Thornley8
(2009)

RCT –
singleblind,
crossover
, placebo
controlle
d

30

50

health, able to
read and write
English and give
written consent

use of psychotropic drugs,
chronic oral d/o that would
prevent the use of oral
NRT products, current use
of nicotine products other
than cigarettes, pregnancy
or breast feeding, weight
<45 kg or >120 kg, blood
pressure BP >180/>100 or
unwillingness to abstain
from smoking prior to or
during the study day

Same as
McRobbie
(2010)

Same as McRobbie
(2010)

W/D

Interventions

N/A

Nicotine
Cannon;
Nicotine
lozenge (4mg);
Mini-lozenge
(4mg);
Nicotine
inhaler

3

Zonnic 1
mg/dose mouth
spray (two
sprays between
the cheek and
gums q1h;
more
frequently if
needed);
Zonnic 2.5mg
lozenges;
Nicorette 4mg
chewing gum
(one piece each
hour; more
frequently if
needed)
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Zonnic 4mg
oral nicotine
pouch;
Nicotine
chewing gum
(4 mg); one
pouch/piece of
gum per hour
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OUTCOMES MEASURED
Outcomes measured across all three studies included withdrawal symptoms,
adverse effects of NRT usage, and temporary abstinence from smoking throughout the
duration of the study days. McRobbie et al and Thornley et al measured the following
withdrawal symptoms: craving, irritability, difficulty concentrating, and restlessness.
These were measured on a 100mm visual analog scale (VAS; 0= not at all; 100=
extremely) every five minutes for a total of 60 minutes after the participant used the NRT
product.7,8 These researchers also measured the adverse effects (AEs) of mouth and
throat irritation, aching jaw, feeling sick, vomiting, flatulence/belching, stomachache,
heartburn, diarrhea, hiccups, feeling high, feeling dizzy, headache, palpitations,
sweatiness, and cold hands/feet based upon their frequency (never, often, or sometimes)
and their strength (weak, moderate, and strong).7,8 The measurement for AEs as well as
the measurement for temporary smoking cessation were made at the completion of each
study day.
Shahab et al measured the withdrawal symptoms of depressed mood, irritability,
restlessness, hunger, and poor concentration on a Moods and Physical Symptoms Scale
(MPSS). This study also measured time spent with urges and strength of urges to smoke
on a six-point Likert scale. Adverse effects, measured on a 10-point scale (0= none; 10=
extreme), included feeling unwell, nausea, throat irritation, and dizziness. All of these
measurements were taken via questionnaire before (0 minutes), during (3, 6, 10 minutes)
and after NRT usage (13, 16, 20 minutes).9 Temporary smoking cessation was also
measured at both one and ten hours after NRT usage.
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The author focused on the withdrawal symptom of craving; however, the
dichotomous data on adverse effects and temporary smoking cessation supported the
research question.
RESULTS
Because the research question focuses on the prevention of craving, only the data
regarding that withdrawal symptom will be presented in the following section. The data
pertaining to two common adverse effects (mouth/throat irritation and feeling sick) as
well as that of temporary smoking cessation provided support for the research question,
so that data will be explained here too.
Two of the randomized-controlled trials compared various types of NRT to
placebo and one of the randomized-controlled trials compared a new type of NRT to
older types of NRT. The Thornley et al trial consisted of three study days, each separated
by three days when the participants were instructed to smoke normally. The McRobbie
et al trial consisted of four study days, each separated by three days when the participants
were instructed to smoke normally. Finally, the Shahab et al trial consisted of four study
days, each separated by seven days when the participants were instructed to smoke
normally.
In the study by Thornley et al, 27 out of the 30 original participants completed the
three study days. It was found that the active nicotine pouch was significantly superior in
decreasing the participants’ craving than the placebo pouch (p= 0.002); furthermore,
there was a mean change in craving from baseline of -23.1 for the active pouch and only
a mean change of -8.7 for the placebo pouch, making the mean difference -14.4 (Table
2).8 The gum did not significantly decrease craving in comparison to placebo (p= 0.22).
Table 3 displays the data for treatment effect, showing that in comparison to the placebo
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(41%), both the gum (52%) and the active pouch (75%) allowed more participants to
remain abstinent throughout the study days.8 The relative benefit increase (RBI) was
calculated to be 26.8% for the gum and 82.9% for the pouch; the absolute benefit
increase (ABI) was 11% for the gum and 34% for the pouch. Finally, the numbers
needed to treat (NNT) was nine for the gum and three for the pouch (Table 3). This
means that nine people have to use the gum and three people have to use the active pouch
in order for one person to temporarily abstain from tobacco use.
Table 4 displays the data describing two common adverse effects of both types of
NRT versus placebo. The gum (33%) and the active pouch (13%) caused more people to
feel sick than placebo (7%); similarly, the gum (47%) and the active pouch (50%) caused
more people to experience mouth irritation than placebo (37%).8 The numbers needed to
harm (NNH) were calculated for the gum and active pouch for both of the adverse
effects. The NNH for feeling sick was four for the gum and 17 for the active pouch.
This means that for every four people that use the gum and for every 17 people that use
the active pouch, one person will feel sick. The NNH for mouth irritation was 10 for the
gum and eight for the active pouch (Table 4).
Table 2. Mean change in craving from baseline to 60 minutes after taking medication8
Mean
Mean difference with placebo
Treatment
p-value
h
(95%
CI)
Active pouch
-23.1
-14.4 (-24.1 to -4.8)
0.002
Gum
-15.4
-6.7 (-16.4 to 2.9)
0.22
Placebo
-8.7
----------------------------------Table 3. Temporary smoking cessation until 5:30pm on study days8
CER

EER

RBI

ABI

NNT

41%

Gum: 52%

Gum: 26.8%

Gum: 11%

Gum: 9

Active pouch: 75%

Active pouch: 82.9%

Active pouch: 34%

Active pouch: 3
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Table 4. Adverse effects of the gum and active pouch vs. placebo8
Adverse event

CER

EER

RRI

ARI

NNH

Feeling sick

7%

Mouth
irritation

37%

Gum: 33%
Active pouch: 13%
Gum: 47%
Active pouch: 50%

Gum: 371.4%
Active pouch: 85.7%
Gum: 27%
Active pouch: 35.1%

Gum: 26%
Active pouch: 6%
Gum: 10%
Active pouch: 13%

Gum: 4
Active pouch: 17
Gum: 10
Active pouch: 8

In the study by McRobbie et al, 44 out of the 47 participants completed all four
study days. Table 5 shows that all three NRT products significantly reduced the
withdrawal symptom of craving more than placebo. There was a mean change in craving
from baseline of -24.7 for the lozenge, -25.8 for the gum, and -28.6 for the mouth spray
in comparison to -8.9 for placebo, making the mean differences -15.8, -16.9, and -19.7
respectively (Table 5).7 Table 6 displays the data for treatment effect, showing that in
comparison to the placebo (19%), the lozenge (45%), gum (55%) and the mouth spray
(53%) allowed more participants to remain tobacco free throughout the study days.7 The
RBI was calculated to be 137% for the lozenge, 190% for the gum, and 179% for the
mouth spray; the ABI was 26% for the lozenge, 36% for the gum, and 34% for the mouth
spray. Finally, the NNT was four for the lozenge, three for the gum, and three for the
mouth spray (Table 6).
Table 7 displays the data describing two common adverse effects of the NRTs
versus placebo. The lozenge (38%), gum (34%), and mouth spray (36%) caused more
people to feel sick than placebo (4%); similarly, the lozenge (25%), gum (30%), and
mouth spray (45%) cause more people to experience mouth irritation than placebo (4%).7
The NNH was calculated for the lozenge, gum, and mouth spray for both of the adverse
effects. The NNH for feeling sick was three for all types of NRT (Table 7). The NNH
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for mouth irritation was five for the lozenge, four for the gum, and two for the mouth
spray (Table 7).
Table 5. Mean change in craving from baseline to 60 minutes after taking medication7
Treatment

Mean change

-24.7

Mean difference with placebo (95%
CI) to -7.9)
-15.8 (-23.7

Lozenge
Gum
Mouth spray
Placebo

p-value

<0.0001

-25.8
-28.6
-8.9

-16.9 (-24.8 to -9.0)
-19.7 (-27.6 to -11.7)
------------------

<0.0001
<0.0001
------------------

Table 6. Temporary smoking cessation until 5:30pm on study days7
CER

EER

RBI

ABI

NNT

19%

Lozenges: 45%

Lozenges: 137%

Lozenge: 26%

Lozenge: 4

Gum: 55%

Gum: 190%

Gum: 36%

Gum: 3

Mouth spray:
53%

Mouth spray: 179%

Mouth spray:
34%

Mouth spray: 3

Table 7. Adverse effects of the lozenge, gum, and mouth spray vs. placebo7
Adverse
Feeling sick

CER
4%

Mouth
irritation

4%

EER
Lozenge: 38%
Gum: 34%
Mouth spray: 36%
Lozenge: 25%
Gum: 30%
Mouth spray: 45%

RRI
Lozenge: 85%
Gum: 80%
Mouth spray: 75%
Lozenge: 525%
Gum: 650%
Mouth spray: 1025%

ARI
Lozenge: 34%
Gum: 30%
Mouth spray: 32%
Lozenge: 21%
Gum: 26%
Mouth spray: 41%

NNH
Lozenge: 3
Gum: 3
Mouth spray: 3
Lozenge: 5
Gum: 4
Mouth spray: 2

In the study by Shahab et al, 48 people participated in comparing the new
Nicotine Cannon (NC) to pre-existing forms of NRT (lozenge, mini-lozenge, gum, and
inhaler). The researchers of this study did not provide the author with dichotomous data;
therefore, NNT and NNH could not be calculated. Shahab et al found that there were
statistically significant reductions in both time spent with urges to smoke and strength of
those urges from before NRT use to after NRT use across all types of NRT that were
tested in this trial (p <0.0001) (Table 8).9 Compared to the lozenge, mini-lozenge, and
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nicotine inhaler, NC usage resulted in less reported adverse side effects, making it more
attractive to those who are interested in smoking cessation.
Table 8. Reduction in withdrawal symptoms across all NRT products from before to after
use9
Withdrawal Symptom
Time spent with urges
Strength of urges

F-score
(1, 236) = 27.5
(1, 213) = 40.9

p-value
<0.0001
<0.0001

DISCUSSION
In compiling the data across all three of the articles that were analyzed in this
systematic review, the conclusion can be drawn that nicotine replacement therapy is more
effective than placebo in preventing the withdrawal symptom of craving in smokers who
are attempting to quit in the short term. However, with the small sample sizes and short
study times, it is impossible to make such a generalized statement about the long term
usage of NRT and smoking cessation.
Nicotine replacement therapy is widely available in the United States. The
transdermal patch, lozenges, and gum are all available over the counter and do not require
a prescription.10 However, it is important to inform your doctor that you are attempting to
quit smoking and using an over-the-counter NRT product. The high amounts of nicotine
in cigarettes change the body’s metabolism; therefore, removing tobacco products from
one’s body may change the management of other chronic health problems. The mouth
spray, nasal spray, and nicotine inhaler all require a prescription from a doctor, physician
assistant, or other licensed medical provider.10
One of the major roadblocks to NRT usage is insurance coverage. Although it is
improving, most private and state based insurances do not cover the entire cost of NRT.
The American Lung Association has been making efforts to demonstrate how important it
is for insurance companies to offer coverage for smoking cessation products. Currently,
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only six states require Medicaid to cover smoking cessation products and only nine states
require private insurances to cover smoking cessation products.11 Last year, the federal
government started providing coverage for smoking cessation products and counseling
sessions for all of its employees.11 With additional support from insurance companies,
smokers will have more of an incentive to quit their habit and prevent many of the health
complications that result from long term tobacco use.
All three of the studies included in this review had similar limitations and flaws in
the performance of the research. The sample size of less than 50 participants for each
study did not allow for adequate heterogeneity in order to be able to make a general
statement about the efficacy of NRT among all types of dependent smokers. All three
studies allowed the participants to smoke on the days in between the short 9-hour study
days. In reality, smokers are not supposed to alternate using NRT with smoking
cigarettes. Therefore, these studies did not adequately assess the correct usage of the
products. Long term usage of these products could lead to the development of more
adverse reactions that may affect people’s compliance with the therapy.
CONCLUSION
According to the three studies in this review, nicotine replacement therapy is a
safe and effective treatment in preventing the withdrawal symptom of craving in
dependent smokers who are attempting to quit. However, the various limitations of the
three included studies inhibit the author from generalizing the effectiveness of NRT to
the entire population of dependent smokers. In future studies, it will be important to
increase the sample size and the length of time that the participants use the NRT
products. It is necessary to eliminate the series of non-study days in between study days
in order to evaluate the correct usage of NRT. It would be interesting to divide the
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participants according to the length of time that they have been smoking and frequency of
their habit to see if NRT works equally as well for those with a longer and heavier habit
history than others. Another possibility for further research would be to start a
longitudinal study that assesses smoker’s health before attempting to quit, follows them
through the quitting process, and then checks in with them at certain intervals to see how
successful they were in the long term.
Smoking cessation is a challenging and personal process; with continued research
and support from insurance companies, dependent smokers will be able to successfully
quit their habits and live healthier and longer lives.
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